Upregulation of mitochondrial NAD+ levels impairs the clonogenicity of SSEA1+ glioblastoma tumor-initiating cells

다국어 초록 (Multilingual Abstract)

Emerging evidence has emphasized the importance of cancer therapies targeting an abnormal metabolic state of tumor-initiating cells (TICs) in which they retain stem cell-like phenotypes and nicotinamide adenine dinucleotide (NAD+) metabolism. However, the functional role of NAD+ metabolism in regulating the characteristics of TICs is not known. In this study, we provide evidence that the mitochondrial NAD+ levels affect the characteristics of glioma-driven SSEA1+ TICs, including clonogenic growth potential. An increase in the mitochondrial NAD+ levels by the overexpression of the mitochondrial enzyme nicotinamide nucleotide transhydrogenase (NNT) significantly suppressed the sphere-forming ability and induced differentiation of TICs, suggesting a loss of the characteristics of TICs. In addition, increased SIRT3 activity and reduced lactate production, which are mainly observed in healthy and young cells, appeared following NNT-overexpressed TICs. Moreover, in vivo tumorigenic potential was substantially abolished by NNT overexpression. Conversely, the short interfering RNA-mediated knockdown of NNT facilitated the maintenance of TIC characteristics, as evidenced by the increased numbers of large tumor spheres and in vivo tumorigenic potential. Our results demonstrated that targeting the maintenance of healthy mitochondria with increased mitochondrial NAD+ levels and SIRT3 activity could be a promising strategy for abolishing the development of TICs as a new therapeutic approach to treating aging-associated tumors.

참고문헌 (Reference)

1 Wu J, "WldS enhances insulin transcription and secretion via a SIRT1-dependent pathway and improves glucose homeostasis" 60 : 3197-3207, 2011

2 Schultz MB, "Why NAD(+)declines during aging : it’s destroyed" 23 : 965-966, 2016

3 Vander Heiden MG, "Understanding the Warburg effect : the metabolic requirements of cell proliferation" 324 : 1029-1033, 2009

4 Vlashi E, "The metabolic state of cancer stem cells-a valid target for cancer therapy?" 79 : 264-268, 2015

5 Verdin E., "The many faces of sirtuins: coupling of NAD metabolism, sirtuins and lifespan" 20 : 25-27, 2014

6 Guarente L, "The many faces of sirtuins : sirtuins and the Warburg effect" 20 : 24-25, 2014

7 Pavlova NN, "The emerging hallmarks of cancer metabolism" 23 : 27-47, 2016

8 Stein LR, "The dynamic regulation of NAD metabolism in mitochondria" 23 : 420-428, 2012

9 DeBerardinis RJ, "The biology of cancer : metabolic reprogramming fuels cell growth and proliferation" 7 : 11-20, 2008

10 Mouchiroud L, "The NAD(+)/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling" 154 : 430-441, 2013

11 Ryall JG, "The NAD(+)-dependent SIRT1 deacetylase translates a metabolic switch into regulatory epigenetics in skeletal muscle stem cells" 16 : 171-183, 2015

12 VanLinden MR, "Subcellular distribution of NAD+ between cytosol and mitochondria determines the metabolic profile of human cells" 290 : 27644-27659, 2015

13 Shyh-Chang N, "Stem cell metabolism in tissue development and aging" 140 : 2535-2547, 2013

14 Chen Y, "Sirtuin-3 (SIRT3), a therapeutic target with oncogenic and tumor-suppressive function in cancer" 5 : e1047-, 2014

15 Satoh A, "Sirt1 extends life span and delays aging in mice through the regulation of Nk2 homeobox 1 in the DMH and LH" 18 : 416-430, 2013

16 Llorens-Bobadilla E, "Single-cell transcriptomics reveals a population of dormant neural stem cells that become activated upon brain injury" 17 : 329-340, 2015

17 Son MJ, "SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma" 4 : 440-452, 2009

18 Finley LW, "SIRT3opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization" 19 : 416-428, 2011

19 Abdel Khalek W, "SIRT3, a mitochondrial NAD(+)-dependent deacetylase, is involved in the regulation of myoblast differentiation" 9 : e114388-, 2014

20 Kim HS, "SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress" 17 : 41-52, 2010

21 Hirschey MD, "SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome" 44 : 177-190, 2011

22 Alhazzazi TY, "SIRT3 and cancer:tumor promoter or suppressor?" 1816 : 80-88, 2011

23 Ma CY, "SIRT1 suppresses self-renewal of adult hippocampal neural stem cells" 141 : 4697-4709, 2014

24 Fan W, "SIRT1 regulates UV-induced DNA repair through deacetylating XPA" 39 : 247-258, 2010

25 Boutant M, "SIRT1 metabolic actions : Integrating recent advances from mouse models" 3 : 5-18, 2014

26 Price NL, "SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function" 15 : 675-690, 2012

27 Rodriguez RM, "Role of sirtuins in stem cell differentiation" 4 : 105-111, 2013

28 Son MJ, "Restoration of mitochondrial NAD+ levels delays stem cell senescence and facilitates reprogramming of aged somatic cells" 34 : 2840-2851, 2016

29 Pirinen E, "Pharmacological Inhibition of poly(ADP-ribose)polymerases improves fitness and mitochondrial function in skeletal muscle" 19 : 1034-1041, 2014

30 Giralt A, "Peroxisome proliferator-activated receptor-gamma coactivator-1alpha controls transcription of the Sirt3 gene, an essential component of the thermogenic brown adipocyte phenotype" 286 : 16958-16966, 2011

31 Di Lisa F, "Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD+ and is a causative event in the death of myocytes in postischemic reperfusion of the heart" 276 : 2571-2575, 2001

32 Rodgers JT, "Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1" 434 : 113-118, 2005

33 Son MJ, "Nicotinamide overcomes pluripotency deficits and reprogramming barriers" 31 : 1121-1135, 2013

34 Lopert P, "Nicotinamide nucleotide transhydrogenase(Nnt)links the substrate requirement in brain mitochondria for hydrogen peroxide removal to the thioredoxin/peroxiredoxin(Trx/Prx)system" 289 : 15611-15620, 2014

35 Yang Y, "NAD+ metabolism: bioenergetics, signaling and manipulation for therapy" 1864 : 1787-1800, 2016

36 Ying W, "NAD+ as a metabolic link between DNA damage and cell death" 79 : 216-223, 2005

37 Zhang H, "NAD(+)repletion improves mitochondrial and stem cell function and enhances life span in mice" 352 : 1436-1443, 2016

38 Canto C, "NAD(+)metabolism and the control of energy homeostasis : a balancing act between mitochondria and the nucleus" 22 : 31-53, 2015

39 Son MJ, "Mitofusins deficiency elicits mitochondrial metabolic reprogramming to pluripotency" 22 : 1957-1969, 2015

40 Wang W, "Mitochondrial DNA damage level determines neural stem cell differentiation fate" 31 : 9746-9751, 2011

41 Harvey AJ, "Metaboloepigenetic regulation of pluripotent stem cells" 2016 : 1816525-, 2016

42 Jang H, "Metabolism in embryonic and cancer stemness" 38 : 381-388, 2015

43 Vlashi E, "Metabolic state of glioma stem cells and nontumorigenic cells" 108 : 16062-16067, 2011

44 Ito K, "Metabolic requirements for the maintenance of self-renewing stem cells" 15 : 243-256, 2014

45 Zhou Y, "Metabolic alterations in highly tumorigenic glioblastoma cells : preference for hypoxia and high dependency on glycolysis" 286 : 32843-32853, 2011

46 Capela A, "LeX is expressed by principle progenitor cells in the embryonic nervous system, is secreted into their environment and binds Wnt-1" 291 : 300-313, 2006

47 Heikal AA, "Intracellular coenzymes as natural biomarkers for metabolic activities and mitochondrial anomalies" 4 : 241-263, 2010

48 Son MJ, "Interference with the mitochondrial bioenergetics fuels reprogramming to pluripotency via facilitation of the glycolytic transition" 45 : 2512-2518, 2013

49 Wang RH, "Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1mutant mice" 14 : 312-323, 2008

50 Singh SK, "Identification of human brain tumour initiating cells" 432 : 396-401, 2004

51 Sancho P, "Hallmarks of cancer stem cell metabolism" 114 : 1305-1312, 2016

52 Wu LE, "Geroncogenesis : metabolic changes during aging as a driver of tumorigenesis" 25 : 12-19, 2014

53 Zhang T, "Enzymes in the NAD+ salvage pathway regulate SIRT1 activity at target gene promoters" 284 : 20408-20417, 2009

54 Cheong JH, "Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models" 10 : 2350-2362, 2011

55 Alano CC, "Differences among cell types in NAD(+) compartmentalization: a comparison of neurons, astrocytes, and cardiac myocytes" 85 : 3378-3385, 2007

56 Hikosaka K, "Deficiency of nicotinamide mononucleotide adenylyltransferase 3(nmnat3)causes hemolytic anemia by altering the glycolytic flow in mature erythrocytes" 289 : 14796-14811, 2014

57 Gomes AP, "Declining NAD(+)induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging" 155 : 1624-1638, 2013

58 Pacini N, "Cancer stem cell theory and the warburg effect, two sides of the same coin?" 15 : 8893-8930, 2014

59 Peiris-Pages M, "Cancer stem cell metabolism" 18 : 55-, 2016

60 Flavahan WA, "Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake" 16 : 1373-1382, 2013

61 Lagadinou ED, "BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells" 12 : 329-341, 2013

62 Scheibye-Knudsen M, "A high-fat diet and NAD(+)activate Sirt1 to rescue premature aging in cockayne syndrome" 20 : 840-855, 2014